Company intelligence / Profile preview

DoAI

Sung Nam, California, United Statesdiscoveryowners.com ↗

Ownership: Private
Development stage: Other

Overview

DoAI is developing artificial intelligence-driven solutions for the early detection of cancers, with a primary focus on pancreatic cancer. Their approach leverages advanced medical imaging and genomics data analyzed through proprietary AI algorithms and Nano-Raman spectroscopy. The company aims to provide affordable, effective early diagnostic tools but has not yet reported results from large-scale clinical trials or commercial launches.

Therapeutic areas: Oncology
Modalities: DeviceArtificial intelligence-powered diagnostic technologyNano-Raman-based diagnostic technology
Industry: Medical Imaging

Partnerships

Strategic partnerships with medical institutions and hospitals in Korea and abroad; specific partners are not named in public sources

Beyond the preview

Go deeper on DoAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DoAI.

Explore the full profile